Transplantation of the human ovarian adenocarcinoma cell line, NIH:OVCAR-3 into athymic mice produces two morphologically distinct tumor cell populations (ascites and solid tumors). In the present study, we isolated both tumor cell phenotypes and investigated their relative malignant potential. Since cytoskeletal and morphological changes correlate with metastatic phenotype, expression of the intermediate-filament protein vimentin was compared between ascites and solid tumors. Ascites tumor cells showed a less differentiated epithelial morphology and concurrently expressed higher levels of vimentin. Ascites cells were more efficient in anchorage independent growth when compared with their solid tumor counterpart. Ascites tumor cells were also highly motile compared with the solid tumor cell population (P=0.006). Migration of ascites tumor cells was further enhanced by type IV collagen, hyaluronic acid, and chondroitin sulfate A. Solid tumor cells removed from the same animal, however, were not significantly affected by these agents. From these studies, we conclude that ovarian cancer cells present in ascites are phenotypic variants which are highly motile compared with solid tumor cells isolated from the same animal. Ascites tumor cells with increased motility may contribute to peritoneal seeding and metastasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nagy JA, Herzberg KT, Dvorak JM and Dvorak HF, 1993, Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res, 53, 2631–4.
Olson TA, Mohanraj D, Carson LF and Ramakrishnan S, 1994, Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res, 54, 276–80.
Heuser LS, Miller FN and Gilley-Pietsch C, 1988, Protein leak from normal vasculature due to human malignant ascites. Am J Surg, 155, 765–9.
Sioussat TM, Dvorak HE, Brock TA and Senger DR, 1993, Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys, 15, 15–20.
Dvorak HE, Sioussat TM, Brown LF et al, 1991, Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med, 174, 1275–8.
Dvorak HE, Nagy JA and Dvorak AM, 1991, Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3, 77–85.
Feldman GB and Knapp RC, 1974, Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol, 11, 991–4.
Mills GB, May C, Hill M et al, 1990, Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest, 86, 851–5.
Mills GB, May C, McGill M et al, 1988, A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res, 48, 1066.
Takahashi Y, Chiba T, Inaba S et al, 1990, Clinico-pathologic evaluation of retroperitoneal lymph node metastasis in ovarian carcinoma Nippon Sanka Fujinka Gakkai Zasshi, 42, 1489–94.
Gritzmann N, Karnel F, Imhof H et al, 1986, Abdominal computerized tomography in the after-care of ovarian cancers Digital Bilddiagn, 6, 171–5.
Dauplat H, Hacker NF, Nieberg RK et al, 1987, Distant metastases in epithelial ovarian carcinoma. Cancer, 60, 1561–6.
Vinokurov VL, 1986, Factors affecting the incidence of metastasis of malignant epithelial tumors of the ovaries. Vopr Onkol, 32, 44–9.
Marks JR, Davidoff AM, Kerns BJ et al, 1991, Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res, 51, 2979–84.
Hamilton, TC, Young RC, McKoy WM et al, 1983, Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res, 43, 5379–89.
Alves VA, Wakamatsu A, Kanamura CT, Magalhaes ES and Siqueira SA, 1992, The importance of fixation in immunohistochemistry: distribution of vimentin and cytokeratins in samples fixed in alcohol and formaldehyde. Rev Hosp Clin Fac Med Sao Paulo, 47, 19–24.
Boon ME and Kok LP, 1991, Formalin is deleterious to cytoskeleton proteins: do we need to replace it by Fomalin-free Kryofix? Eur J Morphol, 29, 173–80.
Trowbridge IS, Lesley J and Schulte R, 1982, Murine cell surface transferrin receptor: studies with an anti-receptor monoclonal antibody. J Cell Physiol, 112, 403–10.
Veatch AL, Carson LF and Ramakrishnan S, 1994, Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian cancer cells. Int J Cancer, 58, 393–9.
Viale G, Gambacorta M, Dell'Orto P and Coggi C, 1988, Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: an immunocytochemical study of eighty-three cases. Virchows Arch A Pathol Anat Histopathol, 413, 91–101.
Thompson EW, Paik S, Brunner N et al, 1992, Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol, 150, 534–44.
Boyer B, Tucker GC, Valles AM, Franke WW and Thiery JP, 1989, Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol, 109, 1495–509.
Van de Molengraft F, Ramaekers F, Jap P, Vooijs P and Mungyer G, 1986, Changing intermediate-sized filament patterns in metastatic hepatocellular carcinoma cells of the guinea pig, Virchows Arch B Cell Pathol, 51, 285–301.
Ramaekers FCS, Haag D, Kant A, Moesker O, Jap PHK and Vooijs GP, 1983, Coexpression of keratin-and vimentin-type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci USA, 80, 2618–22.
Gabbiani G, Kapanci Y, Barazzone P and Franke WW, 1981, Immunochemical identification of intermediate sized filaments in human neoplastic cells. Am J Pathol, 104, 206–16.
Ramaekers FCS, Puts JJG, Kant A et al, 1982, Antibodies to intermediate filaments as a tool in tumor diagnosis. Cell Biol Int Rep, 6, 652–3.
Sridhar KS, Ohnuma T, Plasse TF and Holland JF, 1988, Simultaneous soft agar cloning of ascites and solid tumor specimens from patients with ovarian cancer. Cancer, 62, 1577–81.
Sommers CL, Thompson EW, Torri JA et al, 1991, Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Different, 2, 65–72.
Chen WC and Obrink B, 1991, Cell-cell contacts mediated by E-cadherin (uvomorulin) restrict invasive behavior of L-cells. J Cell Biol, 114, 319–27.
Frexen UH, Behrens J, Sachs M et al, 1991, E-cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol, 113, 173–85.
Behrens J, Mareel MM, Van Roy FM and Birchmeier W, 1989, Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol, 108, 2435–47.
Nagafuchi A, Shirayoshi Y, Okazaki K, Yasuda K and Takeichi M, 1987, Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature, 329, 341–3.
Hashimoto M, Niwa O, Nitta Y, Takeichi M and Yokoro K, 1989, Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res, 80, 459–63.
Birch M, Mitchell S and Hart IR, 1991, Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res, 51, 6660–7.
Sy MS, Guo YJ and Stamenkovic I, 1991, Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med, 174, 859–66.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Veatch, A.L., Carson, L.F. & Ramakrishnan, S. Phenotypic variations and differential migration of NIH:OVCAR-3 ovarian carcinoma cells isolated from athymic mice. Clin Exp Metast 13, 165–172 (1995). https://doi.org/10.1007/BF00132204
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00132204